Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1Genitourinary 1

Conditions

Uterine Cervical Neoplasms 12Recurrence 3Gestational Trophoblastic Disease 3Endometrial Neoplasms 3Cervical Cancer Metastatic 2Uterine Neoplasms 1Sarcoma 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Ovarian Neoplasms 1Neoplasm Metastasis 1Locally Advanced Cervical Cancer 1Endometrioid Endometrial Cancer 1Carcinoma, Transitional Cell 1Carcinoma, Renal Cell 1Advanced Cervical Cancer 1

Interventions

pembrolizumab 24Nivolumab 15Magnetic Resonance Spectroscopy 7Ipilimumab 6avelumab 5atezolizumab 5Specimen Handling 5Docetaxel 4lenvatinib 3durvalumab 3Paclitaxel 3Cyclophosphamide 3Carboplatin 3zanidatamab 2fludarabine 2cabozantinib 2aldesleukin 2Interleukin-2 2Fluorodeoxyglucose F18 2FAPI-46 2veliparib 1tislelizumab 1spartalizumab 1soluble LAG-3 protein, human 1sargramostim 1sacituzumab govitecan 1rucaparib 1regorafenib 1poly ICLC 1olaparib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Carcinoma, Transitional Cell × camrelizumab × Gynecologic × Clear all
NCT03827837 2022-07-01

Famitinib Plus Anti-PD1 Therapy for Advanced Urinary System Tumor, Advanced Gynecological Tumors

Jiangsu HengRui Medicine Co., Ltd.

Phase 2 Unknown
265 enrolled
GenitourinaryGynecologic

Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡